Why Madrigal Pharmaceuticals (MDGL) Is Up 8.9% After Positive Two-Year Rezdiffra Data in MASH Cirrhosis

• Madrigal Pharmaceuticals recently presented positive two-year clinical data for its Rezdiffra therapy in patients with compensated MASH cirrhosis at the Jefferies London Healthcare Conference on November 20, 2025.
• This milestone underscores the company’s expanding investment in both personnel and research to address increasing demand for advanced MASH therapies.
• We will examine how the encouraging clinical results for Rezdiffra shape Madrigal’s long-term outlook and competitive position.

Find companies with promising cash flow potential yet trading below their fair value.

Madrigal Pharmaceuticals Investment Narrative Recap

Madrigal Pharmaceuticals’ investment case centers on belief in Rezdiffra’s potential to establish a leading position in MASH treatment, supported by patent exclusivity, upcoming international launches, and a growing addressable market. The recently announced positive two-year clinical data for Rezdiffra addresses a key short-term catalyst, successful advancement in late-stage trials, while the greatest near-term risk remains heavy dependence on this single therapy, particularly as competition intensifies and reimbursement discussions progress. The positive study results reinforce the catalyst, but do not eliminate the risk of future data or commercial challenges.

Among the company’s recent announcements, Madrigal’s ongoing Phase 3 outcomes trial for Rezdiffra in compensated MASH cirrhosis patients is especially relevant to this news, as it may further define the therapy’s value proposition in a real-world setting. The additional equity awards to support workforce expansion reflect the scale needed for commercial rollout and confirm the importance of execution around these clinical and commercial milestones.

In contrast, investors should be aware that even with promising trial data, risks around reimbursement and payer adoption could still...

Read the full narrative on Madrigal Pharmaceuticals (it's free!)

Madrigal Pharmaceuticals' outlook anticipates $2.5 billion in revenue and $822.9 million in earnings by 2028. This outcome is based on a 68.6% annual revenue growth rate and a $1.1 billion increase in earnings from the current -$281.9 million.

Uncover how Madrigal Pharmaceuticals' forecasts yield a $563.80 fair value, a 6% downside to its current price.

Exploring Other Perspectives

Community members on Simply Wall St submitted five separate fair value estimates for Madrigal Pharmaceuticals, ranging from US$460 to US$2,910, signaling unusually wide differences in outlook. Despite recent positive trial data, heavy reliance on Rezdiffra means ongoing clinical success and payer traction will shape future perceptions and performance, be sure to explore several perspectives before making decisions.

Explore 5 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth 23% less than the current price!

Build Your Own Madrigal Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com